학술논문
A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC?
Document Type
Article
Author
Source
In: Cancer Chemotherapy and Pharmacology . (Cancer Chemotherapy and Pharmacology, March 2024, 93(3):225-236)
Subject
Language
English
ISSN
14320843
03445704
03445704